Avient (AVNT) is back in focus after its latest quarterly update, which combined record adjusted EBITDA margins, mixed GAAP earnings, and an outlook centered on higher value materials for defense, healthcare, and other specialized end markets.
See our latest analysis for Avient.
Avient’s recent earnings update, higher adjusted margins, and dividend affirmation have coincided with a sharp improvement in momentum, with a 90 day share price return of 51.81% and a 1 year total shareholder return that is roughly flat. This suggests the latest move is more about a shift in expectations than long term compounding so far.
If you are looking beyond Avient and want more ideas tied to specialized materials demand, it could be worth scanning our 24 power grid technology and infrastructure stocks as a starting list of potential opportunities.
With the shares up 51.81% over 90 days, trading at $42.75 against an average analyst target around $44 to $47.38 and an indicated intrinsic discount of 18.65%, you have to ask: is there still a buying opportunity here, or is the market already pricing in future growth?
Most Popular Narrative: 23.7% Undervalued
Avient’s most followed narrative pegs fair value at $56.00, well above the last close at $42.75. This sets up a bullish long term earnings story built around higher value materials and margin expansion.
Health care customers are increasingly specifying Avient materials for medical devices, equipment and drug delivery systems. The company is ramping non PFAS and functional additive offerings for these uses, which can support continued organic sales growth and a richer mix that favors net margins and earnings.
Want to see how this plays out in the numbers? The narrative leans on steadier top line growth, a sharp lift in profitability and a future earnings multiple that still steps down from today. Curious which earnings path and margin profile need to line up to justify $56.00 as fair value, even after discounting cash flows at an 8.4% rate?
Result: Fair Value of $56.00 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, you still have to weigh softer demand in key cyclical markets and the risk that higher capital spending for defense capacity may not translate into the earnings analysts expect.
Find out about the key risks to this Avient narrative.
Another View: Earnings Multiple Flags a Rich Price
The bullish $56.00 fair value leans on higher future earnings, but today Avient trades on a P/E of 47.8x versus a fair ratio of 28.4x, the US Chemicals industry at 26.8x and peers at 26.5x. That is a wide gap, so is optimism already built into the price?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
Does this setup feel more optimistic or cautious to you? Take a moment to look through the full picture yourself, including 2 key rewards and 4 important warning signs.
Ready for more investment ideas?
If you stop with just one stock here, you could miss out on other opportunities that better fit your goals, risk comfort, and time horizon.
- Target income first by checking out 13 dividend fortresses, a curated set of companies offering higher yields with an eye on resilience.
- Spot potential mispriced opportunities by running through 55 high quality undervalued stocks, where the focus is on quality businesses trading below their assessed worth.
- Prioritize peace of mind with 81 resilient stocks with low risk scores, highlighting companies that pair more measured risk profiles with solid fundamentals.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com